arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

NEUROCRINE BIOSCIENCES INC

NBIX
$163.42 ▲ +3.60 (+2.25%) at close
Healthcare ·Biological Products, (No Diagnostic Substances) ·USBiological Products, (No Diagnostic Substances)
68 Visible periods
29 Metrics
Peer-ranked Benchmarks
Price Chart
81
Health
Excellent
Bullish
auto_awesome

Analytical Summary

NEUROCRINE BIOSCIENCES INC shows strong fundamentals with top-quartile Return on Common Equity (%) and Profit Margin (%). The company's metrics support a bullish outlook for growth-oriented investors.

Market Cap $16.5B
Dividend Yield
Revenue Growth 39.5%
Op. Margin 15.8%
ROIC 3.7%
FCF / Share $1.27
Trailing P/E 114.3x
Price / Book 4.5x
FCF Yield 0.8%
Debt / Equity
info Valuation on last close. End-of-day price, Aug 7, 2026.

68-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$959.00M
↑ +39.5%
Net Income Profit after all expenses
$144.40M
↑ +34.3%
Operating Margin Operating profit as % of sales
15.8%
↓ -33.5% 78th
FCF / Share Free cash flow per share
$1.27
↓ -6.4%
trending_up

Bullish Indicators

  • Operating Margin (%)Operating Margin (%) is in the top quartile
  • Profit Margin (%)Profit Margin (%) is in the top quartile
  • Return on Common Equity (%)Return on Common Equity (%) is in the top quartile
warning

Bearish Risks

  • No bearish risks detected.

Health Breakdown

Profitability
81
Returns
80
Cash Quality
81

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 18 years · 68 quarters